search
close_mark
pharmcetical-service-banner
  • Overview
  • Our Clients
  • Regulatory Writing
    Services
  • Lean Authoring
    Method
  • eCTD Viewer
  • eCTD Templates
  • Publishing and Submissions
  • Testimonials
  • Resources

With specialized expertise and a deep understanding of both technical and medical writing, Celegence Pharmaceutical teams provide comprehensive regulatory writing services that support drug development programs from early-stage INDs to NDAs, MAAs, and beyond. Our team excels in creating precise, compliant, and high-quality documents that meet the stringent requirements of regulatory authorities.

We offer end-to-end support from technical writing for CMC documentation to medical writing for clinical study reports and safety summaries. We have extensive industry experience and collaborative approach to ensure that submission documents are delivered on time and to the highest standards, helping clients achieve successful regulatory outcomes.

Image

CMC Technical Writing Services

Image

Medical Writing Services

Industry Leaders Trust Celegence

Regulatory Writing Service Types

1

Technical Writing


Drug Master File (DMF) (M1, M2, M3)

  • US: Type I, Type II, Type III, Type IV
  • EDQM: ASMF/CEP
  • ROW: DMFs (China, Korea, Brazil)

CMC Writing (M2, M3)

  • Application Types: MAA, BLA, NDA, IND, CTA, Renewals, Variations
  • Regions: US, Europa, EAEU, Asia Pacific and RoW markets

Learn More

left-arrow

2

Medical Writing


Clinical Writing (M2, M5)

  • CSR
  • Protocols
  • Investigator’s Brochure
  • Overviews
  • Summaries

Non-Clinical Writing (M2, M4)

  • Overviews
  • Toxicology
  • Mutagenicity
  • Summaries

Learn More

left-arrow

3

Safety Writing


  • PSUR/DSUR
  • Line Listings
  • PV Documents
  • PRAC Submissions

LEAN AUTHORING METHOD

Lean authoring offers a transformative approach to streamline submissions, reduce redundancy, and improve compliance outcomes. By emphasizing clarity and structured documentation, this method is helping organizations tackle the evolving regulatory challenges for pharmaceuticals, medical devices, and beyond.

Lean Authoring Checklist

Download now to unlock your access to the Lean Authoring Checklist and discover actionable steps to streamline your regulatory submissions.

Image

Cloud eCTD viewer and dossier management for electronic publishing and submissions

Our proprietary cloud-based dossier management solution eliminates manual steps in the exchange of regulatory dossiers. It allows you to share, view, and review eCTD, NeeS, and other dossier formats from any region and access them in any location.

The hybrid solution offers you cloud-based software as a service whilst keeping your data privately stored on-site or in a virtual private cloud.

Dossplorer_LOGO_White

Features of Dossplorer™ eCTD Viewer:


  • Automated import of dossiers and sequences
  • SaaS solution
  • Intuitive search functionality
  • Explore holistic views across dossiers worldwide
  • Personalized navigation tree utilizing metadata already present in dossiers
  • Multiple dossier formats supported
  • Advanced restrictions
  • Integrated eCTD viewer with Single Sign-on solutions
infograminc

Intuitive MS Word templates for eCTD-ready documents without software installation

DosscriberTM helps stand-alone regulatory documents for, amongst others, NDA/BLA, IND, NDS, MAA, CTA, PIP, scientific advice, and briefing packages.

With consistent document structure, naming, and eCTD-readiness, Dosscriber™ templates facilitate repurposing documents across countries, products, and dossier types – without rework.

Dossplorer_LOGO_White

Features of eCTD Document Templates:


  • Embedded fonts and paragraph styles
  • Structured information in tabular formats
  • Multiple options for granularity
  • Prefilled document headers, footers, and properties
  • Regulatory (ICH) guidance and experience
  • MS Word document templates with content control boxes

End-To-End Publishing &
Submission Services

  • Investigational New Drug Application (INDA)

    Image
  • Submitted to CDER.

  • Required after pre-clinical studies but before initiating a clinical trial.

  • Request for FDA authorization to administer an investigational drug to humans.

  • Investigator IND: Submitted by Physician.

  • Emergency IND: to authorize use of an experimental drug in an emergency situation.

  • Treatment IND: submitted for experimental drugs showing promise in clinical testing for serious or immediate life-threatening.

  • Abbreviated New Drug Application (ANDA)

    Image
  • Submitted for the review and approval of a generic drug.

  • Termed abbreviated because this submission is generally not required to include pre-clinical and clinical data.

  • Drug must demonstrate therapeutic equivalence to a previously approved “reference listed drug”.

  • Drug must demonstrate therapeutic equivalence to a previously approved “reference listed drug”.

  • Biological License Application (NDA)

    Image
  • Submitted to CBER.

  • Submitted for vaccines, blood and blood components, somatic cells, gene therapy, and other biological drug products.

  • New Drug Application (NDA)

    Image
  • Regulatory procedure through which sponsors propose FDA to approve a new pharmaceutical drug.

  • Must establish the safety and efficacy of the drug in its proposed use.

  • Manufacturing methods and controls adequately preserves the drug’s strength, quality and purity.

Your Trusted Partner for Regulatory Writing

Ben Dowd

Senior Manager, Regulatory Affairs, Fulcrum Therapeutics

“Working with Celegence on our publishing and submission activities has delivered significant value. Their client-focused approach, combined with deep regulatory knowledge and smart tools like Dossplorer, enabled real-time collaboration and faster decision-making. Thanks to their support, we were able to meet tight deadlines without compromising quality—cutting publishing time significantly for major submissions and reducing rework substantially. Celegence’s professionalism, responsiveness, and commitment to our success have made them an essential extension of our internal team. We’re confident that with Celegence, we have the right partner to support our regulatory operations moving forward.

Caroline Mandret,

Regulatory Operations Manager, Stallergenes Greer

“We are very satisfied with our collaboration with Celegence. For several years now, we have been relying on them for the XEVMPD submission of our data. On the strength of this positive experience, we have extended their scope of intervention to include data entry in LifeSphere and are now embarking on a new project to enrich our IDMP data in this same solution. Their in-depth expertise and perfect understanding of regulatory requirements, combined with a pragmatic, results-oriented approach, have significantly enhanced the quality and efficiency of our data management processes. What sets Celegence apart is their ability to quickly identify our specific needs and propose tailor-made solutions, which is a key factor in our success. Their structured and proactive support enables us to reach important milestones with serenity and clarity. As we continue to transform our regulatory operations, choosing Celegence as our long-term partner was a natural strategic decision. We look forward to continuing this fruitful collaboration.

Jason Mattis

Head Global CMC Regulatory Affairs, Kenvue

“I have been working with Celegence for several years and very much appreciate their partnership on so many levels. Celegence has very strong CMC experience and not only provided us much needed consultant services, but they also worked with us to utilize and leverage industry-disrupting digital solutions, Dossplorer™ and CAPTIS®. These tools have changed how we access and use our own data. Dossplorer™ (a dossier viewing tool) was upgraded with industry leading features such as translation, a goggle-like power search, document compare and many others that drastically reduce the time it takes to perform change impact assessments, document comparisons, translation and search within non-English documents and the ability to upload many other critical Health Authority documents keeping our dossiers fully compliant and current. Since Dossplorer could be used by anyone in Kenvue, it gave this power to all our stakeholders and business partners as well. CAPTIS® (an AI enabled technical/medical writing tool) was piloted with the CMC team in Kenvue to see where we could leverage using AI to author Module 3 quality submission ready documents. The Celegence team was able to automate technical writing for 5+ of the most frequently written Module 3 quality submission documents to streamline our life cycle management workload and resources. The documents Celegence provided using their AI tool were shown to be remarkably reliable when compared to manual preparation. This pilot showed the art of possible. We achieved great things with Celegence and appreciate their collaboration and expertise.

Bimpe Shitta-Bey

Regulatory Strategy Lead, Recursion Pharmaceuticals

“Partnering with Celegence for our publishing and submissions has been a game-changer. Their combination of knowledgeable, client-focused experts and technology-enabled services has dramatically improved our efficiency. The use of Dossplorer’s real-time review and commenting capabilities played a pivotal role in meeting tight submission deadlines. From collaborative document preparation to seamless eCTD publishing, their tools and expertise have directly accelerated our submission and approval timelines. With Celegence’s support, we cut our publishing time in half, minimized rework, and consistently met aggressive timelines. Their responsiveness and commitment to excellence make them one of our most reliable business partners. I would never hesitate to recommend their services."

Ron Celeste

President, ThinSpring

“Celegence has consistently demonstrated the value of their tech-enabled services in improving efficiency and compliance. The use of eCTD templates saves significant hours of document readiness and rework – streamlining the preparation and reducing publishing timelines. These templates consistently deliver hard returns on investment, helping organizations save time and resources. Additionally, the use of Dossplorer’s real-time review and comments feature was instrumental in meeting submission timelines, which otherwise might not have been achievable. From document collaboration to seamless publishing, Celegence’s tools and expertise are driving measurable time-to-market improvements and enabling success where it matters most. Celegence’s tech-enabled services consistently deliver immediate value. Qdossier supported by eCTD submission experts, allowed us to cut our publishing time for a full New Drug Application in half. Rework was minimized, allowing us to meet aggressive timelines. Customer service responsiveness is top-notch. Celegence is the best business partner we’ve had in our 25 years. We managed to publish a full NDA with a very aggressive timeline; we have successfully submitted it to the FDA just 12 working days after we started publishing the first set of documents. A total of 645 PDF files have been published, 450 dataset files have been included, and almost 2000 hyperlinks have been created in this dossier. The submission itself has been reviewed by the customer directly in Dossplorer, which was a key solution with this challenging timeline.

Christian Klewitz

Head of Data Management, B Braun

“The [Celegence] team – and I explicitly mean the entire team – are experts in nearly everything you need to run your regulatory business successfully: it goes without saying that the regulatory expertise (e.g., XEVMPD, ISO-IDMP, Submission, etc.) is excellent, but it’s the knowledge and result-based approaches that make the “wow” effect: troubleshooting, extinguishing fires, development of new (and successful) ideas, Excel-magic. Just state your problem and get options for solutions that work. They are great!

Contact Us Today

From document publishing automation to eCTD submissions and beyond, Celegence is your trusted partner for regulatory affairs excellence. Contact us to learn how we can help you achieve your compliance goals efficiently and cost-effectively.

"*" indicates required fields